MX2019010980A - Antagonistas del receptor opioide kappa y productos y metodos relacionados al mismo. - Google Patents
Antagonistas del receptor opioide kappa y productos y metodos relacionados al mismo.Info
- Publication number
- MX2019010980A MX2019010980A MX2019010980A MX2019010980A MX2019010980A MX 2019010980 A MX2019010980 A MX 2019010980A MX 2019010980 A MX2019010980 A MX 2019010980A MX 2019010980 A MX2019010980 A MX 2019010980A MX 2019010980 A MX2019010980 A MX 2019010980A
- Authority
- MX
- Mexico
- Prior art keywords
- opioid receptor
- products
- kappa opioid
- receptor antagonists
- methods related
- Prior art date
Links
- 102000048260 kappa Opioid Receptors Human genes 0.000 title abstract 3
- 108020001588 κ-opioid receptors Proteins 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 229940123257 Opioid receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se proporcionan compuestos que antagonizan el receptor opioide kappa (KOR) y productos que contienen dichos compuestos, así como los métodos de su uso y síntesis. Tales compuestos tienen la estructura de la Fórmula (I), o un isómero, racemato, hidrato, solvato, isótopo o sal farmacéuticamente aceptable del mismo: (FORMULA) en donde X, Y, R1, R2, R4, R5 R6, R7, R8 y R11 son como se definen en la presente.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762473209P | 2017-03-17 | 2017-03-17 | |
| US201762585447P | 2017-11-13 | 2017-11-13 | |
| US201762609960P | 2017-12-22 | 2017-12-22 | |
| PCT/US2018/023027 WO2018170492A1 (en) | 2017-03-17 | 2018-03-16 | Kappa opioid receptor antagonists and products and methods related thereto |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019010980A true MX2019010980A (es) | 2020-02-10 |
| MX388721B MX388721B (es) | 2025-03-20 |
Family
ID=61911695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019010980A MX388721B (es) | 2017-03-17 | 2018-03-16 | Antagonistas del receptor opioide kappa y productos y metodos relacionados al mismo. |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10676469B2 (es) |
| EP (3) | EP4574210A3 (es) |
| JP (1) | JP7132237B2 (es) |
| KR (1) | KR102656163B1 (es) |
| CN (1) | CN110914262B (es) |
| AU (1) | AU2018234931B2 (es) |
| CA (1) | CA3056426A1 (es) |
| DK (1) | DK3596069T3 (es) |
| ES (1) | ES2926533T3 (es) |
| IL (1) | IL269313B2 (es) |
| MX (1) | MX388721B (es) |
| SG (1) | SG11201908633SA (es) |
| WO (1) | WO2018170492A1 (es) |
| ZA (1) | ZA201906107B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240343719A1 (en) * | 2017-03-17 | 2024-10-17 | The Scripps Research Institute | Kappa opioid receptor antagonists and products and methods related thereto |
| EP4574210A3 (en) * | 2017-03-17 | 2025-10-15 | The Scripps Research Institute | Kappa opioid receptor antagonists and products and methods related thereto |
| EP3787481B1 (en) | 2018-05-01 | 2023-08-23 | Neumora Therapeutics, Inc. | Machine learning-based diagnostic classifier |
| EP3870030A4 (en) | 2018-10-23 | 2022-08-03 | Blackthorn Therapeutics, Inc. | SYSTEMS AND METHODS FOR SCREENING, DIAGNOSIS AND STRATIFICATION OF PATIENTS |
| JP7487204B2 (ja) | 2018-12-17 | 2024-05-20 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| WO2021148639A1 (en) * | 2020-01-24 | 2021-07-29 | Syngenta Crop Protection Ag | Pesticidally active fused bicyclic heteroaromatic compounds |
| US11266627B1 (en) | 2021-05-04 | 2022-03-08 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| CN114105969A (zh) * | 2020-09-01 | 2022-03-01 | 广东东阳光药业有限公司 | Btrx-335140的晶型及其制备方法 |
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| JP2025508051A (ja) | 2022-03-07 | 2025-03-21 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 大うつ病性障害の治療に使用するためのアチカプラントの多形形態 |
| EP4489730A1 (en) | 2022-03-07 | 2025-01-15 | Janssen Pharmaceuticals, Inc. | Compositions comprising aticaprant |
| CN115611700B (zh) * | 2022-10-11 | 2024-06-14 | 辽宁东大光明化工科技有限责任公司 | 一种1-溴-2,5-二氯-3-氟苯的制备方法 |
| IL322808A (en) * | 2023-02-17 | 2025-10-01 | Scripps Research Inst | Quinoline derivatives used as kappa-opioid receptor agonists |
| WO2024216061A1 (en) * | 2023-04-13 | 2024-10-17 | Neumora Therapeutics, Inc. | Methods of treating depression and anhedonia |
| WO2024216046A1 (en) * | 2023-04-13 | 2024-10-17 | Neumora Therapeutics, Inc. | Methods of treating anhedonia |
| US12171758B1 (en) * | 2023-07-05 | 2024-12-24 | Neumora Therapeutics, Inc. | Crystalline salt forms of kappa opioid receptor antagonist and products and methods related thereto |
| WO2025038420A1 (en) | 2023-08-11 | 2025-02-20 | Neumora Therapeutics, Inc. | Kappa opioid receptor antagonist and methods and products related thereto |
| TW202515866A (zh) * | 2023-09-05 | 2025-04-16 | 大陸商西藏海思科製藥有限公司 | Kor拮抗劑及其在醫藥上的應用 |
| WO2025250535A1 (en) * | 2024-05-28 | 2025-12-04 | Neumora Therapeutics, Inc. | Methods of treating depression and anhedonia |
| WO2025257758A1 (en) | 2024-06-11 | 2025-12-18 | Assia Chemical Industries Ltd. | Solid state forms of navacaprant |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL343495A1 (en) * | 1998-04-20 | 2001-08-27 | Basf Ag | Heterocyclically substituted amides used as calpain inhibitors |
| US7399765B2 (en) * | 2003-09-19 | 2008-07-15 | Abbott Laboratories | Substituted diazabicycloalkane derivatives |
| CN102015684A (zh) * | 2007-12-10 | 2011-04-13 | 葛兰素集团有限公司 | 联-吡啶基吡啶酮作为黑色素浓缩激素受体1拮抗剂 |
| CN101925576B (zh) | 2008-01-22 | 2013-02-06 | 伊莱利利公司 | κ-选择性阿片受体拮抗剂 |
| WO2009156889A1 (en) | 2008-06-25 | 2009-12-30 | Pfizer Inc. | Diaryl compounds and uses thereof |
| EP2403847B1 (en) | 2009-03-06 | 2016-03-02 | UCB Biopharma SPRL | Triazine derivatives as kinase inhibitors |
| US8486968B2 (en) * | 2010-12-10 | 2013-07-16 | Boehringer Ingelheim International Gmbh | Compounds |
| CA2882132C (en) * | 2012-08-16 | 2021-07-06 | The Scripps Research Institute | Kappa opioid ligands |
| EP4574210A3 (en) * | 2017-03-17 | 2025-10-15 | The Scripps Research Institute | Kappa opioid receptor antagonists and products and methods related thereto |
-
2018
- 2018-03-16 EP EP25161251.1A patent/EP4574210A3/en active Pending
- 2018-03-16 ES ES18716424T patent/ES2926533T3/es active Active
- 2018-03-16 EP EP18716424.9A patent/EP3596069B1/en active Active
- 2018-03-16 CA CA3056426A patent/CA3056426A1/en active Pending
- 2018-03-16 WO PCT/US2018/023027 patent/WO2018170492A1/en not_active Ceased
- 2018-03-16 DK DK18716424.9T patent/DK3596069T3/da active
- 2018-03-16 US US15/924,119 patent/US10676469B2/en active Active
- 2018-03-16 JP JP2019551287A patent/JP7132237B2/ja active Active
- 2018-03-16 CN CN201880032383.7A patent/CN110914262B/zh active Active
- 2018-03-16 MX MX2019010980A patent/MX388721B/es unknown
- 2018-03-16 EP EP22184496.2A patent/EP4141001B1/en active Active
- 2018-03-16 KR KR1020197030427A patent/KR102656163B1/ko active Active
- 2018-03-16 AU AU2018234931A patent/AU2018234931B2/en active Active
- 2018-03-16 SG SG11201908633S patent/SG11201908633SA/en unknown
-
2019
- 2019-09-12 IL IL269313A patent/IL269313B2/en unknown
- 2019-09-16 ZA ZA2019/06107A patent/ZA201906107B/en unknown
-
2020
- 2020-04-10 US US16/846,136 patent/US11124504B2/en active Active
-
2021
- 2021-07-30 US US17/390,531 patent/US11897873B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018234931A1 (en) | 2019-10-17 |
| KR102656163B1 (ko) | 2024-04-08 |
| EP4141001C0 (en) | 2025-03-05 |
| EP4574210A2 (en) | 2025-06-25 |
| MX388721B (es) | 2025-03-20 |
| BR112019019157A2 (pt) | 2020-04-14 |
| EP4574210A3 (en) | 2025-10-15 |
| US10676469B2 (en) | 2020-06-09 |
| SG11201908633SA (en) | 2019-10-30 |
| WO2018170492A9 (en) | 2018-12-13 |
| US11897873B2 (en) | 2024-02-13 |
| EP3596069A1 (en) | 2020-01-22 |
| CN110914262B (zh) | 2024-04-05 |
| US20210047310A1 (en) | 2021-02-18 |
| CA3056426A1 (en) | 2018-09-20 |
| EP4141001A1 (en) | 2023-03-01 |
| IL269313A (en) | 2019-11-28 |
| ZA201906107B (en) | 2022-03-30 |
| EP3596069B1 (en) | 2022-07-13 |
| JP7132237B2 (ja) | 2022-09-06 |
| IL269313B2 (en) | 2023-03-01 |
| JP2020514374A (ja) | 2020-05-21 |
| ES2926533T3 (es) | 2022-10-26 |
| US20220162202A1 (en) | 2022-05-26 |
| EP4141001B1 (en) | 2025-03-05 |
| DK3596069T3 (da) | 2022-08-01 |
| WO2018170492A1 (en) | 2018-09-20 |
| IL269313B (en) | 2022-11-01 |
| CN110914262A (zh) | 2020-03-24 |
| AU2018234931B2 (en) | 2022-05-26 |
| KR20190139874A (ko) | 2019-12-18 |
| US20190023700A1 (en) | 2019-01-24 |
| US11124504B2 (en) | 2021-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019010980A (es) | Antagonistas del receptor opioide kappa y productos y metodos relacionados al mismo. | |
| MX2018011831A (es) | Antagonistas solubles de receptor de c5aa(c5ar). | |
| MX2018003432A (es) | Compuestos heterociclicos y usos de los mismos. | |
| MX2016011632A (es) | Derivados de azaspiro como antagonistas de trpm8. | |
| MX2015012062A (es) | Inhibidores de jak2 y alk2 y metodos para su uso. | |
| MX2017000485A (es) | Espirocicloheptanos como inhibidores de la cinasa rho (rock). | |
| CR20160291A (es) | Análogos de cortistatina y síntesis y usos de los mismos | |
| UY37073A (es) | Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock, y las composiciones que los contienen | |
| GT201600085A (es) | Composiciones y métodos para modular los receptores x farnesoides | |
| CL2020000363A1 (es) | Inhibidores macrocíclicos de mcl-1 y métodos de uso. | |
| SV2017005405A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
| CO2020000056A2 (es) | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de la fibrosis | |
| DK3774862T3 (da) | Nye GLP-1-analoger | |
| MX2017001554A (es) | Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados utiles para el tratamiento de enfermedades inflamatorias, metabolicas oncologicas y autoinmunitarias. | |
| MX2017002896A (es) | Uso del agente de refuerzo del receptor del acido gamma-aminobutirico tipo a (gabaa) en la preparacion de un sedante y medicamento anestesico. | |
| MX2018003893A (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
| MX2015008993A (es) | Radiofarmaceuticos y agentes de radio-formacion de imagen a base de triazina. | |
| MX2020002436A (es) | Antagonistas del receptor de vasopresina y productos y metodos relacionados a los mismos. | |
| CY1120680T1 (el) | Ανταγωνιστες η3 που περιεχουν συνταξη πυρηνα φαινοξυπιπεριδινης | |
| MX2017016939A (es) | Novedosas antagonistas 5-ht2. | |
| MA53904A (fr) | Composés contenant du deutérium | |
| CL2017002498A1 (es) | Piridopirimidinonas y su uso como modulares del receptor nmda | |
| UY35708A (es) | Compuestos novedosos como antagonistas del receptor de ácido lisofosfatidico | |
| CU24434B1 (es) | Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1 | |
| MX2019003310A (es) | Inhibidores de dopamina-b-hidroxilasa. |